Nutra Pharma (OTCBB: NPHC) Chairman and Chief Executive Officer, Rik J Deitsch, Interviewed by CEOCFO.com
Click Here for Full Article:
Company Profile:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Kevin McKnight1-800-404-8982Undiscovered Equities, Inc.1515 S Federal Hwy, Ste 207Boca Raton, FL 33432www.undiscoveredequities.com
Monday, October 26, 2009
Thursday, October 22, 2009
NutraPharma's (OTCBB: NPHC) distributor, XenaCare to Market its Over-the-Counter Pain Reliever, Cobroxin, in the Official Annual Publication of NASCAR
XenaCare Holdings Has Announced That It Will Begin Marketing Its Over-the-Counter (OTC) Pain Reliever, Cobroxin, in Racing One, the Official Annual Publication of NASCAR
DELRAY BEACH, Fla., Oct 22, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an agreement to market its over-the-counter (OTC) pain reliever, Cobroxin, in Racing One, the official annual publication of NASCAR, for the 2010 racing season. Cobroxin is currently available online at Cobroxin.com and will be available soon at various retail outlets. The 2010 Racing One Annual, which will be available starting at the 52nd anniversary of the NASCAR Sprint Cup DAYTONA 500 in February 2010, will be sold through the end of the season. In addition to reaching approximately 8.5 million NASCAR fans attending the 78 NASCAR events being held at the 26 NASCAR sanctioned racetracks, the Publication will also be sold throughout North America in major newsstands, bookstores, grocery stores, retail outlets, train stations, and airports.
"We are excited to be advertising Cobroxin in the 2010 Racing One Annual, as it offers us the opportunity to build awareness around Cobroxin by introducing it through NASCAR, the fastest growing spectator sport in the United States," commented Frank Rizzo, President of XenaCare Holdings. "We look forward to beginning this campaign and continuing to expand our marketing efforts as we introduce Cobroxin through retailers across the United States," he added.
In addition to the Company's agreement to market Cobroxin in NASCAR's Racing One, XenaCare Holdings will also be advertising Cobroxin in the 2009 NFL Alumni Guide and Yearbook. Additionally, the Company announced plans to begin its initial print marketing campaign this fall, which includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced on Monday that it had begun accepting orders for Cobroxin online at Cobroxin.com. The Company intends to announce both online and brick-and-mortar retailers in the coming weeks as they begin offering Cobroxin for sale to consumers.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.xenacareholdings.com/
http://www.cobroxin.com/
For More information contact:
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
DELRAY BEACH, Fla., Oct 22, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an agreement to market its over-the-counter (OTC) pain reliever, Cobroxin, in Racing One, the official annual publication of NASCAR, for the 2010 racing season. Cobroxin is currently available online at Cobroxin.com and will be available soon at various retail outlets. The 2010 Racing One Annual, which will be available starting at the 52nd anniversary of the NASCAR Sprint Cup DAYTONA 500 in February 2010, will be sold through the end of the season. In addition to reaching approximately 8.5 million NASCAR fans attending the 78 NASCAR events being held at the 26 NASCAR sanctioned racetracks, the Publication will also be sold throughout North America in major newsstands, bookstores, grocery stores, retail outlets, train stations, and airports.
"We are excited to be advertising Cobroxin in the 2010 Racing One Annual, as it offers us the opportunity to build awareness around Cobroxin by introducing it through NASCAR, the fastest growing spectator sport in the United States," commented Frank Rizzo, President of XenaCare Holdings. "We look forward to beginning this campaign and continuing to expand our marketing efforts as we introduce Cobroxin through retailers across the United States," he added.
In addition to the Company's agreement to market Cobroxin in NASCAR's Racing One, XenaCare Holdings will also be advertising Cobroxin in the 2009 NFL Alumni Guide and Yearbook. Additionally, the Company announced plans to begin its initial print marketing campaign this fall, which includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced on Monday that it had begun accepting orders for Cobroxin online at Cobroxin.com. The Company intends to announce both online and brick-and-mortar retailers in the coming weeks as they begin offering Cobroxin for sale to consumers.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.xenacareholdings.com/
http://www.cobroxin.com/
For More information contact:
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Tuesday, October 20, 2009
NutraPharma's (OTCBB:NPHC) Distributor, XenaCare Holdings Announces Agreement to Market OTC Pain Reliever, Cobroxin, in NFL Alumni Publication
Nutra Pharma's (OTCBB: NPHC) Distributor, XenaCare Holdings Announces Agreement to Market OTC Pain Reliever, Cobroxin, in the National Football League (NFL) Alumni Association Publication
XenaCare Holdings Has Signed an Agreement to Advertise Cobroxin in the 2009 NFL Alumni Guide and Yearbook. The Publication Reaches Hundreds of Thousands of Fans Each Year as Well as Current and Past NFL Players, Team Owners, Coaches and League Executives.
DELRAY BEACH, Fla., Oct 20, 2009 XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an advertising agreement with Belmont International to market its over-the-counter pain reliever, Cobroxin, in the 2009 NFL Alumni Guide and Yearbook. Belmont International is the official publisher of the NFL Alumni Guide and Yearbook. The NFL Alumni Guide and Yearbook reaches hundreds of thousands of NFL fans each year. In addition to its public release, the 2009 Publication will also be released under a controlled distribution to current and past players of the league, team owners, coaches, and league executives.
"We are excited to announce this advertising agreement because the NFL Alumni Association not only represents one of the most prestigious sports organizations in North America, but also because it reaches a demographic that we believe will have a strong interest in our pain reliever, Cobroxin," explained Frank Rizzo, President of XenaCare Holdings. "As we move forward with our national launch, we plan to continue announcing our additional marketing outreach campaigns that are designed to help build awareness around Cobroxin and to support our current online sales at Cobroxin.com as well as sales at retailers, both online and brick-and-mortar, where Cobroxin will soon be available," he concluded.
In August, XenaCare Holdings was granted the exclusive license by Nutra Pharma Corporation (OTCBB:NPHC) to market and distribute Cobroxin throughout the United States. In addition to advertising in the NFL Alumni Guide and Yearbook, XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertisements in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://app.streamsend.com/c/6757341/721/o47oCUI/nS0Q?redirect_to=http%3A%2F%2Fwww.XenaCareHoldings.com http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://app.streamsend.com/c/6757341/725/o47oCUI/nS0Q?redirect_to=http%3A%2F%2Fwww.undiscoveredequities.com
XenaCare Holdings Has Signed an Agreement to Advertise Cobroxin in the 2009 NFL Alumni Guide and Yearbook. The Publication Reaches Hundreds of Thousands of Fans Each Year as Well as Current and Past NFL Players, Team Owners, Coaches and League Executives.
DELRAY BEACH, Fla., Oct 20, 2009 XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it has signed an advertising agreement with Belmont International to market its over-the-counter pain reliever, Cobroxin, in the 2009 NFL Alumni Guide and Yearbook. Belmont International is the official publisher of the NFL Alumni Guide and Yearbook. The NFL Alumni Guide and Yearbook reaches hundreds of thousands of NFL fans each year. In addition to its public release, the 2009 Publication will also be released under a controlled distribution to current and past players of the league, team owners, coaches, and league executives.
"We are excited to announce this advertising agreement because the NFL Alumni Association not only represents one of the most prestigious sports organizations in North America, but also because it reaches a demographic that we believe will have a strong interest in our pain reliever, Cobroxin," explained Frank Rizzo, President of XenaCare Holdings. "As we move forward with our national launch, we plan to continue announcing our additional marketing outreach campaigns that are designed to help build awareness around Cobroxin and to support our current online sales at Cobroxin.com as well as sales at retailers, both online and brick-and-mortar, where Cobroxin will soon be available," he concluded.
In August, XenaCare Holdings was granted the exclusive license by Nutra Pharma Corporation (OTCBB:NPHC) to market and distribute Cobroxin throughout the United States. In addition to advertising in the NFL Alumni Guide and Yearbook, XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertisements in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://app.streamsend.com/c/6757341/721/o47oCUI/nS0Q?redirect_to=http%3A%2F%2Fwww.XenaCareHoldings.com http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://app.streamsend.com/c/6757341/725/o47oCUI/nS0Q?redirect_to=http%3A%2F%2Fwww.undiscoveredequities.com
Wednesday, October 14, 2009
BUYINS.NET Issues Nutra Pharma SqueezeTrigger Report Approximately 12.92 Million Shares Shorted Since January 2005 (OTCBB: NPHC)
Press Release Source: BUYINS.NET
On 1:14 pm EDT, Wednesday October 14, 2009
NEWPORT BEACH, Calif., Oct. 14, 2009
http://www.buyins.net/, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTCBB:NPHC - News) after releasing the latest short sale data to July 2009. From January 2005 to October 2009, approximately 167.8 million total aggregate shares of NPHC have traded for a total dollar value of nearly $46.7 million. The total aggregate number of shares shorted in this time period is approximately 12.92 million shares. The NPHC SqueezeTrigger price of $0.28 is the volume weighted average short price of all short selling in NPHC. A series of short squeezes has begun as shares of NPHC have jumped from $0.03 to a recent high of $0.99. With the stock at $0.51 currently, 69% of all shares shorted in NPHC are now out-of-the-money. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net/.
A detailed NPHC report is at: http://www.buyins.com/reports/nphc10-10-09.pdf
Click here to view SqueezeTrigger: http://www.buyins.com/images/nphcstr10-14-09.jpg
Click here to view Friction Factor: http://www.buyins.com/images/nphcff10-10-09.jpg
Friction Factor is used to calculate if a fair market is being made in the shares of NPHC. 60% of recent trading days are positive or bullishly-biased and 40% of trading days are negative or bearishly biased. Days where trading was abnormal shows 100% bullish and 0% bearish biases, which means that there is a bullishly-biased market being made in NPHC in the past 32 trading days.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
On 1:14 pm EDT, Wednesday October 14, 2009
NEWPORT BEACH, Calif., Oct. 14, 2009
http://www.buyins.net/, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTCBB:NPHC - News) after releasing the latest short sale data to July 2009. From January 2005 to October 2009, approximately 167.8 million total aggregate shares of NPHC have traded for a total dollar value of nearly $46.7 million. The total aggregate number of shares shorted in this time period is approximately 12.92 million shares. The NPHC SqueezeTrigger price of $0.28 is the volume weighted average short price of all short selling in NPHC. A series of short squeezes has begun as shares of NPHC have jumped from $0.03 to a recent high of $0.99. With the stock at $0.51 currently, 69% of all shares shorted in NPHC are now out-of-the-money. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net/.
A detailed NPHC report is at: http://www.buyins.com/reports/nphc10-10-09.pdf
Click here to view SqueezeTrigger: http://www.buyins.com/images/nphcstr10-14-09.jpg
Click here to view Friction Factor: http://www.buyins.com/images/nphcff10-10-09.jpg
Friction Factor is used to calculate if a fair market is being made in the shares of NPHC. 60% of recent trading days are positive or bullishly-biased and 40% of trading days are negative or bearishly biased. Days where trading was abnormal shows 100% bullish and 0% bearish biases, which means that there is a bullishly-biased market being made in NPHC in the past 32 trading days.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Nutra Pharma Announces Online Availability of Cobroxin for the Treatment of Moderate to Severe Chronic Pain (OTCBB: NPHC)
Nutra Pharma’s Over-the-Counter Treatment for Moderate to Severe Chronic Pain, Cobroxin, is Now Available for Sale Online at Cobroxin.com. The Company Plans to Announce Additional Retail Partnerships as Its Moves Through the Fourth Quarter of 2009 and into the First Quarter of 2010.
Press Release Source: Nutra Pharma Corp. On 9:00 am EDT, Wednesday October 14, 2009PLANTATION, Fla. - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
•All Natural
•Non-Addictive
•Non-Narcotic
•Non-Opiate
•More Potent than Morphine
•Long Lasting
“We are excited that Cobroxin is now officially available for sale,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States,” he concluded.
In August, Nutra Pharma announced that it had granted XenaCare Holdings (OTCBB: XCHO - News) the exclusive license to market and distribute Cobroxin throughout the United States. XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Contact:Kevin McKnight
1-800-404-8982
1515 S Federal Hwy STE 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Press Release Source: Nutra Pharma Corp. On 9:00 am EDT, Wednesday October 14, 2009PLANTATION, Fla. - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
•All Natural
•Non-Addictive
•Non-Narcotic
•Non-Opiate
•More Potent than Morphine
•Long Lasting
“We are excited that Cobroxin is now officially available for sale,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States,” he concluded.
In August, Nutra Pharma announced that it had granted XenaCare Holdings (OTCBB: XCHO - News) the exclusive license to market and distribute Cobroxin throughout the United States. XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Contact:Kevin McKnight
1-800-404-8982
1515 S Federal Hwy STE 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Wednesday, October 7, 2009
Nutra Pharma (OTCBB: NPHC) Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
Nyloxin Rx, which Was Developed by Nutra Pharma’s Drug Discovery Subsidiary, ReceptoPharm, Is a Prescription Medicine Launching in Late-2009 for the Treatment of Severe (Stage 3) Chronic Pain.
Press Release Source: Nutra Pharma Corp. On 7:30 am EDT, Wednesday October 7, 2009PLANTATION, Fla. - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.
Nyloxin Rx is a prescription pain reliever produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating Stage 3 pain, which is the most severe pain that inhibits one’s ability to fully function. Additionally, Nyloxin Rx does not rely on the use of opioids for its pain relieving action, but, instead, uses a novel mechanism from cobra venom peptides for treating pain.
“For the past 10 years, we have allocated significant time and resources to the study of peptides from cobra venom for the treatment of several indications, including pain,” explained Dr. Paul Reid, CEO of ReceptoPharm. “Given the amount of clinical evidence using cobra venom as a pain reliever, the drug’s well-defined safety profile, and the active pharmaceutical ingredient, which is a monographed drug under United States Homeopathic Pharmacopoeia, we plan to go directly to market with Nyloxin Rx and begin introducing it to physicians later this year,” he added.
According to a report published by IMS Health, there were a total of 237 million U.S. opioid prescriptions in 2008 with over 85 million prescriptions specifically for the treatment of chronic pain. Additionally, a December 2008 article in the Journal Gazette reported that sales of Oxycodone (not including Percodan) totaled $2.89 billion and that sales of Fentanyl totaled $1.55 billion from January to October of the same year.
“We are excited to be launching Nyloxin Rx as a prescription pain reliever at a time when both physicians and patients are actively looking for alternatives to opioid-based pain therapies. We are confident that Nyloxin Rx will compete successfully with other prescription pain medicines and become the preferred treatment for severe chronic pain,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “While we continue to focus on bringing Nyloxin Rx to market, we are also planning to use our financial and strategic resources to begin additional human clinical trials in the near-term for our other drug indications outside of pain,” he concluded.
For more information go to http://www.nyloxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Nyloxin Rx, which Was Developed by Nutra Pharma’s Drug Discovery Subsidiary, ReceptoPharm, Is a Prescription Medicine Launching in Late-2009 for the Treatment of Severe (Stage 3) Chronic Pain.
Press Release Source: Nutra Pharma Corp. On 7:30 am EDT, Wednesday October 7, 2009PLANTATION, Fla. - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.
Nyloxin Rx is a prescription pain reliever produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating Stage 3 pain, which is the most severe pain that inhibits one’s ability to fully function. Additionally, Nyloxin Rx does not rely on the use of opioids for its pain relieving action, but, instead, uses a novel mechanism from cobra venom peptides for treating pain.
“For the past 10 years, we have allocated significant time and resources to the study of peptides from cobra venom for the treatment of several indications, including pain,” explained Dr. Paul Reid, CEO of ReceptoPharm. “Given the amount of clinical evidence using cobra venom as a pain reliever, the drug’s well-defined safety profile, and the active pharmaceutical ingredient, which is a monographed drug under United States Homeopathic Pharmacopoeia, we plan to go directly to market with Nyloxin Rx and begin introducing it to physicians later this year,” he added.
According to a report published by IMS Health, there were a total of 237 million U.S. opioid prescriptions in 2008 with over 85 million prescriptions specifically for the treatment of chronic pain. Additionally, a December 2008 article in the Journal Gazette reported that sales of Oxycodone (not including Percodan) totaled $2.89 billion and that sales of Fentanyl totaled $1.55 billion from January to October of the same year.
“We are excited to be launching Nyloxin Rx as a prescription pain reliever at a time when both physicians and patients are actively looking for alternatives to opioid-based pain therapies. We are confident that Nyloxin Rx will compete successfully with other prescription pain medicines and become the preferred treatment for severe chronic pain,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “While we continue to focus on bringing Nyloxin Rx to market, we are also planning to use our financial and strategic resources to begin additional human clinical trials in the near-term for our other drug indications outside of pain,” he concluded.
For more information go to http://www.nyloxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Monday, October 5, 2009
Manas Petroleum founder Heinz Scholz and CEO Erik Herlyn are interviewed by Cash.ch
Swiss based Manas petroleum (OTCBB: MNAP) has the chance to become a large player in the petroleum businesses. This exploration Company has drilling rights for gigantic oil reserves. Supervisory board president and founder Heinz Scholz and CEO Erik Herlyn are interviewed by Cash.ch.
Schulz and Herlyn want to build Manas Petroleum into what "World Finance" last year simply stated "the next large oil group".
Follow this link to the full story: http://www.prweb.com/releases/manas/albania/prweb2992524.htm
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Schulz and Herlyn want to build Manas Petroleum into what "World Finance" last year simply stated "the next large oil group".
Follow this link to the full story: http://www.prweb.com/releases/manas/albania/prweb2992524.htm
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Online Financial Publication, CEO-CFO, Interviews Nutra Pharma Chairman and CEO (OTCBB: NPHC)
Online Financial Publication, CEO-CFO, Interviews Nutra Pharma Chairman and CEO (OTCBB: NPHC) - Nutra Pharma Has Announced That Its Chairman and CEO, Rik J. Deitsch, Was Interviewed by the Senior Editor of CEO-CFO, Lynn Fosse. the Interview, Which Will Be Published in Late-October, Focuses on Nutra Pharma's Launch of Its Pain Reliever, Cobroxin, and the Company's Growth Strategies
Press Release Source: Nutra Pharma Corp.
On Monday October 5, 2009, 9:00 am EDT PLANTATION, Fla.-- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J. Deitsch, has completed an interview with leading online financial publication, CEO-CFO.
In the interview, Mr. Deitsch discusses the launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain developed by Nutra Pharma's drug discovery subsidiary, ReceptoPharm. Additionally, Mr. Deitsch also discusses the company's growth strategy as it relates to future potential acquisitions and out-licensing partnerships.
"It is a very exciting time for Nutra Pharma. As the company realizes its first significant revenues through the sale of our drug products, it is more important than ever that we share the story of Nutra Pharma with our investors and the public," explained Mr. Deitsch. "As excitement builds around the launch of Cobroxin and the development of our other leading drug indications, we plan to extend our communication outreach to include consumer-oriented media outlets in addition to financial industry publications," he concluded.
CEO-CFO is a weekly online financial publication that combines news and interviews from key executives at publicly-traded companies and venture capital firms in the United States and abroad. The interview with Mr. Deitsch is scheduled for publication in late-October. Once the interview is published on CEO-CFO, a direct link will be made available on the Nutra Pharma website.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
disclaimer: http://www.undiscoveredequities.com/disclaimer_np.html
CONTACT: Kevin McKnight
Undiscovered Equities, Inc
Tel: +1 800 404 8982
WWW: http://www.undiscoveredequities.com
Press Release Source: Nutra Pharma Corp.
On Monday October 5, 2009, 9:00 am EDT PLANTATION, Fla.-- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J. Deitsch, has completed an interview with leading online financial publication, CEO-CFO.
In the interview, Mr. Deitsch discusses the launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain developed by Nutra Pharma's drug discovery subsidiary, ReceptoPharm. Additionally, Mr. Deitsch also discusses the company's growth strategy as it relates to future potential acquisitions and out-licensing partnerships.
"It is a very exciting time for Nutra Pharma. As the company realizes its first significant revenues through the sale of our drug products, it is more important than ever that we share the story of Nutra Pharma with our investors and the public," explained Mr. Deitsch. "As excitement builds around the launch of Cobroxin and the development of our other leading drug indications, we plan to extend our communication outreach to include consumer-oriented media outlets in addition to financial industry publications," he concluded.
CEO-CFO is a weekly online financial publication that combines news and interviews from key executives at publicly-traded companies and venture capital firms in the United States and abroad. The interview with Mr. Deitsch is scheduled for publication in late-October. Once the interview is published on CEO-CFO, a direct link will be made available on the Nutra Pharma website.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
disclaimer: http://www.undiscoveredequities.com/disclaimer_np.html
CONTACT: Kevin McKnight
Undiscovered Equities, Inc
Tel: +1 800 404 8982
WWW: http://www.undiscoveredequities.com
Subscribe to:
Posts (Atom)